Deliver easier up-titration with Rasuvo® (methotrexate) injection. Multiple dosing options let you optimize treatment to fit your patients’ needs. Remember to begin optimizing dosage within 3 months of starting MTX therapy.1
Modify your patient’s dose at no additional cost to the patient, as their optimal dose of Rasuvo is being determined.
When adjusting your patient’s dosage before their current monthly prescription has run out, your patient can receive 2 doses of the new prescription at no additional cost. This can occur up to 2 times over the course of their therapy. Simply fill out the form and fax it to (800) 582-0022.
References: 1. Smolen JS, et al. Ann Rheum Dis. 2014;73:492-509. 2. Pichlmeier U, et al. Clin Exp Rheumatol. 2014;32:563-571. 3. Braun J, et al. Arthritis Rheum. 2008;58:73-81. 4. Kromann CB, et al. J Dermatol Treat. 2015;26(2):188-190. 5. Rasuvo® [prescribing Information]. Chicago, IL: Medac Pharma, Inc.; November 2014. 6. Pachon JA, et al. SAGE Open Medicine. 2014: 2:1-12.
Rasuvo is indicated for the:
Common adverse reactions are: nausea, abdominal pain, dyspepsia, stomatitis/mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leukopenia, pancytopenia, dizziness, photosensitivity, and "burning of skin lesions". The most frequently reported adverse reactions include ulcerative stomatitis, leukopenia, nausea, and abdominal distress. Other frequently reported adverse reactions are malaise, undue fatigue, chills and fever, dizziness and decreased resistance to infection.
Rasuvo is for once weekly subcutaneous use only.
Administer Rasuvo in the abdomen or thigh.